CMMB shows substantial cash burn acceleration with operating cash flow deteriorating meaningfully while stockholders' equity declined over 40% year-over-year.
The company's operating cash outflow increased substantially to $20.4M from $12.4M, indicating accelerated cash burn that raises questions about runway sustainability. Combined with the significant decline in stockholders' equity and overall asset base shrinkage of one-third, this suggests the biotech is consuming capital rapidly to fund operations without corresponding revenue generation.
CMMB's financial position deteriorated notably across key metrics, with operating cash burn increasing substantially while total assets contracted by 33% to $43.1M. Stockholders' equity declined by over 40% to $36.2M, reflecting the capital consumption pattern typical of clinical-stage biotechs but at an accelerated pace. The company maintained its cash position relatively better at $13.5M (down 11%), though the widening cash burn gap signals potential funding needs in the near term.
Capex reduced 71.5% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
Operating cash flow fell 64.6% — earnings quality concerns; investigate working capital changes and non-cash items.
Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.
Current assets declined 33.4% — monitor working capital adequacy and short-term liquidity.
Total assets contracted 33.1% — asset sales, write-downs, or balance sheet optimization underway.
Cash decreased 11% — monitor burn rate and upcoming capital needs.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →